文献速递血液透析通路

药物涂层球囊与普通球囊治疗失功透析通路的系统评价与荟萃分析

Drug-Coated Balloon Versus Plain Balloon Angioplasty for the Treatment of Dysfunctional Dialysis Access: A Systematic Review and Meta-analysis.
PubMed 文献 · J Endovasc Ther · 2025-08-14

系统评价25项RCT共2838例患者,比较药物涂层球囊(DCBA)与普通球囊(PBA)治疗失功透析通路的疗效与安全性,DCBA在6、12个月靶病变及通路初级通畅率均优于PBA并降低靶病变血运重建率,但12个月时DCBA与高压球囊(HPBA)在靶病变初级通畅率上无显著差异。

要点

  • DCBA较PBA提高6、12个月靶病变及通路初级通畅率并降低靶病变血运重建率
  • 12个月时DCBA与HPBA在靶病变初级通畅率上无显著差异
  • DCBA与PBA的技术成功率和全因死亡率无显著差异

核心结论

  • DCBA较PBA改善靶病变初级通畅率和通路初级通畅率并降低靶病变血运重建率。
  • DCBA在12个月靶病变初级通畅率上较HPBA无显著优势。
  • DCBA与PBA的技术成功率和全因死亡率相似。

研究设计与样本

  • 系统评价与荟萃分析,纳入25项比较DCBA与PBA的随机对照试验(RCT),共2838例患者。
  • 采用随机效应模型计算风险比(RR)及95%置信区间(CI),并预设亚组分析(DCBA vs HPBA、DCBA vs SBA)。

主要发现

  • DCBA较PBA提高6个月靶病变初级通畅率(RR 1.27,95%CI 1.12-1.43,p<0.001)和12个月靶病变初级通畅率(RR 1.28,95%CI 1.13-1.45,p<0.001)。
  • DCBA较PBA提高6个月通路初级通畅率(RR 1.25,95%CI 1.04-1.40,p=0.002)和12个月通路初级通畅率(RR 1.42,95%CI 1.23-1.65,p<0.001)。
  • DCBA较PBA降低6个月靶病变血运重建率(RR 0.60,95%CI 0.35-0.80,p=0.003)和12个月靶病变血运重建率(RR 0.79,95%CI 0.68-0.93,p=0.005)。
  • 12个月时DCBA与HPBA的靶病变初级通畅率(RR 1.49,95%CI 0.83-2.67,p=0.181)和通路初级通畅率(RR 1.30,95%CI 0.92-1.84,p=0.133)无显著差异。
  • DCBA与PBA的技术成功率和全因死亡率无显著差异。

关键数值与推荐

  • DCBA较PBA的6个月靶病变初级通畅率RR 1.27(95%CI 1.12-1.43,p<0.001)。
  • DCBA较PBA的12个月靶病变初级通畅率RR 1.28(95%CI 1.13-1.45,p<0.001)。
  • DCBA较PBA的6个月通路初级通畅率RR 1.25(95%CI 1.04-1.40,p=0.002)。
  • DCBA较PBA的12个月通路初级通畅率RR 1.42(95%CI 1.23-1.65,p<0.001)。
  • 12个月DCBA与HPBA的靶病变初级通畅率RR 1.49(95%CI 0.83-2.67,p=0.181)。

临床怎么用

  • 对失功透析通路行球囊扩张时,DCBA较标准球囊可改善通畅并减少再次血运重建。
  • 选择DCBA或HPBA需结合患者个体因素和通路特征,DCBA相对HPBA的额外价值尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal treatment for dysfunctional dialysis access between drug-coated balloon angioplasty (DCBA) and plain balloon angioplasty (PBA), including standard balloon angioplasty (SBA) and high-pressure balloon angioplasty (HPBA), remains unclear. This study aims to compare the efficacy and safety of DCBA and PBA. MATERIALS AND METHODS: A systematic review was conducted to identify randomized controlled trials (RCTs) comparing DCBA and PBA. Outcomes included target lesion primary patency (TLPP), access circuit primary patency (ACPP), target lesion revascularization (TLR), technical success, and all-cause mortality. A meta-analysis with a priori subgroup analysis (ie, DCBA vs HPBA and DCBA vs SBA) was performed using a random-effects model to calculate risk ratios (RRs) and 95% confidence intervals (CIs). RESULTS: Twenty-five RCTs with a total of 2838 patients were included. DCBA showed higher TLPP at 6 months (RR: 1.27, 95% CI: 1.12-1.43, p<0.001) and 12 months (RR: 1.28, 95% CI: 1.13-1.45, p<0.001) than PBA. ACPP was also superior with DCBA at 6 months (RR: 1.25, 95% CI: 1.04-1.40, p=0.002) and 12 months (RR: 1.42, 95% CI: 1.23-1.65, p<0.001). However, no significant difference was found between DCBA and HPBA for TLPP (RR: 1.49, 95% CI: 0.83-2.67, p=0.181) and ACPP (RR: 1.30, 95% CI: 0.92-1.84, p=0.133) at 12 months. TLR was lower with DCBA at 6 months (RR: 0.60, 95% CI: 0.35-0.80, p=0.003) and 12 months (RR: 0.79, 95% CI: 0.68-0.93, p=0.005). No significant difference in the technical success rate and all-cause mortality was observed. CONCLUSIONS: DCBA improves TLPP and ACPP and reduces the TLR rate compared to PBA. However, it shows no significant advantage over HPBA in terms of TLPP and ACPP at 12 months. The technical success rate and all-cause mortality were similar between the 2 approaches.Clinical ImpactThis meta-analysis highlights the differential effectiveness of drug-coated balloon angioplasty (DCBA) compared with standard balloon angioplasty (SBA) and high-pressure balloon angioplasty (HPBA) in dysfunctional dialysis access. DCBA significantly improves primary patency and reduces revascularization rates compared to SBA, supporting its clinical utility. However, no clear advantage was found over HPBA at 12 months. These results suggest that while DCBA offers benefits over SBA, its added value over HPBA remains uncertain. Clinicians should consider individual patient factors and access characteristics when selecting the optimal angioplasty strategy.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Zhang Q, Zou D, Mao W, et al. Drug-Coated Balloon Versus Plain Balloon Angioplasty for the Treatment of Dysfunctional Dialysis Access: A Systematic Review and Meta-analysis. J Endovasc Ther. 2025. PMID: 40814233. doi:10.1177/15266028251359499

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。